IBA and INVAP expand collaboration for CNEA’s proton therapy center in Argentina

By News Release

 IBA (Ion Beam Applications S.A.), a provider of proton therapy solutions, has signed a new collaborative service agreement with INVAP, which will serve and ensure the long-term performance of the National Atomic Energy Commission’s (Comisión Nacional de Energía Atómica - CNEA) future proton therapy center to be installed in Buenos Aires. The signature was made in Buenos Aires at a signing ceremony organized during the Belgian Economic Mission to Argentina in presence of HRH Princess Astrid.

This new contract covers IBA’s & INVAP’s joint operation and maintenance of the Argentine Proteus PLUS* proton therapy system and is based on the in-depth training of a team of INVAP and CNEA’s engineers and technicians who will receive support from IBA specialists in preventive and corrective maintenance, on site and remotely.

In September 2015, IBA signed its first contract with INVAP to supply and install the first proton therapy system in Latin America near the Instituto de Oncología Angel H. Roffo, on the agronomy campus of the University of Buenos Aires (UBA). At the end of December 2017, IBA and INVAP signed a new contract for the supply of an additional gantry treatment room including a unique eye treatment modality. The proton center will now include two gantry treatment rooms with next generation pencil beam scanning capability and integrated cone-beam CT as well as a dedicated research room.

Sabine de Voghel, Corporate Advisor of IBA, commented: “We are delighted to strengthen our presence in Argentina and expand our collaboration with INVAP/CNEA so that our expertise in operating and maintaining proton therapy centers will benefit the first proton therapy center in Latin America and make it a reference center in the region. Besides this first proton therapy project, IBA has one system in operation and four others projects under construction/installation (three with INVAP/CNEA) for the production of radiopharmaceuticals for the diagnosis of severe diseases.”

Vincente Campenni, General Manager and CEO of INVAP, commented: "Proton therapy is used today to treat a wide range of cancers and it can be used where treatment options were previously limited. Proton therapy has the potential to improve treatment results and decrease the risk of secondary effects or long-term complications, leading to improved patients’ quality of life. We are therefore very happy that this collaboration between CNEA, UBA, INVAP and IBA will benefit more cancer patients in Argentina and Latin America.”

Back To Top

IBA and INVAP expand collaboration for CNEA’s proton therapy center in Argentina.  Appl Rad Oncol. 

By News Release| July 10, 2018
Categories:  Section|Technologies

About the Author

News Release

News Release


Copyright © Anderson Publishing, Ltd

    Agility CMS